Linked Life Data

11965373

Source:http://linkedlifedata.com/resource/pubmed/id/11965373

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2002-4-19
pubmed:abstractText
Optimization of the hydrophobic moiety of caprolactam/thiazepinone based compounds led to the identification of potent Src SH2 binders in two different series incorporating a phosphotyrosine group (RU 81843) or a phosphobenzoic group (RU 79181). The X-ray co-structures with the Src SH2 domain revealed different binding modes for RU 81843 and RU 79181, and an excellent fit between RU81843 and the Src SH2 protein thus explaining its high potency (9 nM, 15-fold more potent than pYEEI reference peptide).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0960-894X
pubmed:author
pubmed:issnType
Print
pubmed:day
6
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1291-4
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Discovery of highly potent Src SH2 binders: structure-activity studies and X-ray structures.
pubmed:affiliation
Aventis Pharma, Paris Research Center, Medicinal Chemistry, 102 route de Noisy, 93235 Cedex, Romainville, France. pierre.deprez@aventis.com
pubmed:publicationType
Journal Article